Shanghai Jianfa Zhixin Medical Technology Group Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
On April 17, 2026, the Company held the 14th meeting of the 3rd Board of Directors to review the proposal on the purchase of D&O Insurance. This initiative aims to further improve the Company's risk management system, facilitate the full exercise of rights and responsibilities by directors and senior management, reduce governance and operational risks, and protect the interests of investors. In accordance with the "Corporate Governance Guidelines for Listed Companies" and other relevant regulations, the Company intends to purchase liability insurance for the Company, all directors, senior management, and other relevant responsible personnel (hereinafter referred to as "D&O Insurance"). All directors fulfilled their obligation to abstain from voting on this matter, and the proposal will be submitted directly to the 2025 annual shareholders' meeting for consideration. The specific details are as follows: